Evidence map›Paper›PMID 28540485›Full record

ArticlePathology oncology research : POR2018

XPC Polymorphism and Risk for Lung Cancer in North Indian Patients Treated with Platinum Based Chemotherapy and Its Association with Clinical Outcomes.

Shweta Lawania, Navneet Singh, Digamber Behera, Siddharth Sharma

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Effect ofOncoTargets and therapy · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shweta LawaniaDepartment of Biotechnology, Thapar University, Punjab, 147002, India.
Navneet SinghDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education & Research (PGIMER), Sector 14, Chandigarh, India.
Digamber BeheraDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education & Research (PGIMER), Sector 14, Chandigarh, India.
Siddharth SharmaDepartment of Biotechnology, Thapar University, Punjab, 147002, India. siddharthsharma.phd@thapar.edu.
Post Graduate Institute of Medical Education and Research · INThapar Institute of Engineering & Technology · IN

Funding

Indian Council of Medical Research Grant No. 5/13/126/2011/NCD-III
6 · The paper itself

Abstract

Xeroderma pigmentosum complementation group C plays an important role in the human repair system. As reported in previous studies its polymorphism are associated with lung cancer susceptibility. The purpose of this study is to investigate the association of XPC gene with lung cancer susceptibility, overall response and clinical outcomes amongst North Indians. A hospital based study of 370 lung cancer cases and 370 healthy controls was conducted and genotypes were determined using PCR-RFLP assay. Results were assessed using logistic linear regression adjusted for age, sex and smoking status. Survival analysis was conducted using Kaplan-Meier survival analysis and Cox regression analysis. The treatment outcomes of 167 lung cancer patients treated with platinum based chemotherapy were evaluated.The mutant genotypic variant of XPC Lys

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsAsian PeopleDNA-Binding ProteinsDrug Resistance, NeoplasmFemaleGenetic Predisposition to DiseaseGenotypeHumansIndiaKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedAntineoplastic AgentsDNA-Binding ProteinsPlatinum CompoundsXPC protein, humanLung cancerPlatinum based chemotherapyXeroderma pigmentosum group C;PCR-RFLP;overall survival

Identifiers

PMID28540485
OpenAlexW2619265898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.